These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 20093855)

  • 1. Antibody fragments: hope and hype.
    Nelson AL
    MAbs; 2010; 2(1):77-83. PubMed ID: 20093855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant antibody fragments and immunotoxin fusions for cancer therapy.
    Brinkmann U
    In Vivo; 2000; 14(1):21-7. PubMed ID: 10757057
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics and biodistribution of genetically-engineered antibodies.
    Colcher D; Pavlinkova G; Beresford G; Booth BJ; Choudhury A; Batra SK
    Q J Nucl Med; 1998 Dec; 42(4):225-41. PubMed ID: 9973838
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fab-scFv fusion protein: an efficient approach to production of bispecific antibody fragments.
    Lu D; Jimenez X; Zhang H; Bohlen P; Witte L; Zhu Z
    J Immunol Methods; 2002 Sep; 267(2):213-26. PubMed ID: 12165442
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells.
    Olafsen T; Rasmussen IB; Norderhaug L; Bruland OS; Sandlie I
    Immunotechnology; 1998 Oct; 4(2):141-53. PubMed ID: 9853955
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting and therapy of carcinoembryonic antigen-expressing tumors in transgenic mice with an antibody-interleukin 2 fusion protein.
    Xu X; Clarke P; Szalai G; Shively JE; Williams LE; Shyr Y; Shi E; Primus FJ
    Cancer Res; 2000 Aug; 60(16):4475-84. PubMed ID: 10969795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
    Rohrbach F; Gerstmayer B; Biburger M; Wels W
    Clin Cancer Res; 2000 Nov; 6(11):4314-22. PubMed ID: 11106249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Linear gene fusions of antibody fragments with streptavidin can be linked to biotin labelled secondary molecules to form bispecific reagents.
    Pearce LA; Oddie GW; Coia G; Kortt AA; Hudson PJ; Lilley GG
    Biochem Mol Biol Int; 1997 Sep; 42(6):1179-88. PubMed ID: 9305536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diabodies: small bispecific antibody fragments.
    Holliger P; Winter G
    Cancer Immunol Immunother; 1997; 45(3-4):128-30. PubMed ID: 9435855
    [No Abstract]   [Full Text] [Related]  

  • 12. Medical applications of single-chain antibodies.
    Huston JS; McCartney J; Tai MS; Mottola-Hartshorn C; Jin D; Warren F; Keck P; Oppermann H
    Int Rev Immunol; 1993; 10(2-3):195-217. PubMed ID: 8360586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Generation and characterization of a mouse single-chain antibody fragment specific for disialoganglioside (GD2).
    Moutel S; Birkle S; Laurence V; Michon J; Fridman WH; Aubry J; Teillaud JL
    Hybridoma; 1997 Aug; 16(4):335-46. PubMed ID: 9309424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant immunotoxins for treating cancer.
    FitzGerald DJ; Kreitman R; Wilson W; Squires D; Pastan I
    Int J Med Microbiol; 2004 Apr; 293(7-8):577-82. PubMed ID: 15149034
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
    Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
    J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new model for intermediate molecular weight recombinant bispecific and trispecific antibodies by efficient heterodimerization of single chain variable domains through fusion to a Fab-chain.
    Schoonjans R; Willems A; Schoonooghe S; Leoen J; Grooten J; Mertens N
    Biomol Eng; 2001 Jun; 17(6):193-202. PubMed ID: 11337278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant Antibody Fragments for Neurological Disorders: An Update.
    Manoutcharian K; Gevorkian G
    Curr Neuropharmacol; 2024; 22(13):2157-2167. PubMed ID: 37646225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bispecific and bifunctional single chain recombinant antibodies.
    Kriangkum J; Xu B; Nagata LP; Fulton RE; Suresh MR
    Biomol Eng; 2001 Sep; 18(2):31-40. PubMed ID: 11535414
    [TBL] [Abstract][Full Text] [Related]  

  • 19. T-cell immunotherapy for human MK-1-expressing tumors using a fusion protein of the superantigen SEA and anti-MK-1 scFv antibody.
    Ueno A; Arakawa F; Abe H; Matsumoto H; Kudo T; Asano R; Tsumoto K; Kumagai I; Kuroki M; Kuroki M
    Anticancer Res; 2002; 22(2A):769-76. PubMed ID: 12014649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficient construction of a diabody using a refolding system: anti-carcinoembryonic antigen recombinant antibody fragment.
    Asano R; Kudo T; Nishimura Y; Makabe K; Hayashi H; Suzuki M; Tsumoto K; Kumagai I
    J Biochem; 2002 Dec; 132(6):903-9. PubMed ID: 12473192
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.